Sanofi, an innovative biopharmaceutical company, has appointed Michaela Scheiffert as General Manager Pharma for Central and Southern Europe (MCO) and Pharma Head and Country Lead for Poland. The combination of these two functions underscores the country's growing importance within Sanofi's structures and its influence in shaping healthcare policy in Europe. With the dynamic development of the clinical research ecosystem, digitization and artificial intelligence (AI) applications, Poland is uniquely positioned to support Sanofi's strategic goals in the region. In her new role, Michaela Scheiffert will be responsible for executing the company's global strategy, with a strong focus on immunology and the development of breakthrough therapies.
Sanofi's multinational organization (MCO) structure, which includes Poland, the Czech Republic, Hungary, Romania, Greece, Ukraine, Israel and 15 partner markets in Europe, plays a key role in the pharmaceutical company's global operations. Sanofi serves millions of patients each year, contributing significantly to its extensive research and development (R&D) portfolio, which now includes 78 clinical projects worldwide. A significant portion of Sanofi's clinical research is conducted specifically in the CSE region, underscoring its strategic importan...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
